Indications for use:
– arterial hypertension (increased blood pressure), including in patients over 60 years of age;
– rhythm disturbances associated with an increase in heart rate (supraventricular arrhythmias, extrasystoles);
– prevention of migraine attacks;
– cardiac ischemia;
– heart failure;
– myocardial infarction.
Cardioselective beta blocker without sympathomimetic and membrane stabilizing activity. The main action is hypotensive. Can reduce heart rate. Reduces the severity and frequency of angina attacks, improves the patient’s physical well-being, reduces the risk of recurrent myocardial infarction.
It has a certain antiarrhythmic activity. Most effective for rhythm disturbances with an increase in the number of heartbeats. Egilok slows down the heart rate (HR) by reducing the automatism of the sinus node, slowing down the excitatory impulse, reducing excitability and myocardial contractility.
Prevents a migraine attack.
When taking the product in therapeutic doses, it practically does not affect the smooth muscles of the bronchi and peripheral arteries.
When taken orally, the product has a maximum effect after 1.5 hours after administration. About 5% of the product is excreted unchanged in the urine, the rest is biotransformed in the liver. Therefore, if liver function is impaired, a product accumulation effect may be observed, and dose adjustment may be necessary.
Egilok (Egilok) method of administration and doses:
The dosage is selected by the attending physician in each individual case individually.
With arterial hypertension, the initial average therapeutic dose is 50 mg / day in 1 or 2 doses. If there is no effect or the hypotensive effect is non-cardinal, then it is possible to increase the dosage of the product up to 100-200 mg / day.
With angina pectoris, the product is prescribed at a dosage of 100-200 mg / day in 1 or 2 doses.
With extrasystole and supraventricular arrhythmias, the average therapeutic dose is from 100-200 mg / day in 2 divided doses (morning and evening), if possible evenly distributing the product throughout the day.
For secondary prevention of myocardial infarction, patients are prescribed 200 mg / day in 2 divided doses.
For the prevention of migraine attacks, 100-200 mg / day of the product is prescribed in 2 divided doses (morning and evening).
It should be noted that in patients with severe impairment of kidney and liver function, the product should be dosed with caution, because. cumulation (i.e. accumulation) of the product in the blood is possible.
Egilok (Egilok) contraindications:
– sinus bradycardia with a heart rate of less than 50-60 beats per minute;
– AV – blockade of 2 or 3 degrees;
– sinoatrial blockade;
– syndrome of weakness of the sinus node;
– severe disorders of peripheral circulation;
– arterial hypotension (decrease in blood pressure below 90-100 mm Hg;
– high susceptibility to the components of the product.
Egilok (Egilok) side effects:
From the side of the central nervous system: high fatigue, dizziness, headaches, depression, drowsiness, insomnia, nightmares, decreased ability to concentrate, less often – parasthesia, muscle spasm.
From the senses: rare disorders in the form of visual impairment, conjunctivitis, tinnitus.
From the side of the cardiovascular system: bradycardia (decrease in heart rate), heart failure, less often – conduction disturbance, Raynaud’s syndrome.
From the respiratory system: shortness of breath, bronchospasm, rhinitis can rarely be observed.
From the digestive system: nausea, vomiting, diarrhea, constipation, abdominal pain, dry mouth, abnormal liver function.
On the part of the skin: photodermatosis, urticaria, erythema, psoriasis-like and degenerative skin changes, alopecia (baldness), increased sweating.
Others: thrombocytopenia, weight gain.
The use of the product during pregnancy is possible only if the expected benefit to the mother outweighs the potential risk to the fetus. When using the product during pregnancy, it is necessary to carefully monitor (observe) the state of the fetus in utero, as well as monitor the newborn for several days after childbirth to exclude arterial hypotension, bradycardia (slow heart rate), respiratory depression, hypoglycemia (decrease in blood sugar levels). blood).
Egilok is practically not excreted in breast milk; in the treatment of the mother, constant monitoring of the state of the cardiovascular and respiratory systems of the baby is necessary.
Use with other drugs:
Simultaneous use of Egilok with digitalis products, nitrates, calcium channel blockers, parasympathomimetics and other hypotensive, antianginal (against angina), antiarrhythmic products increase the risk of arterial hypotension (collapse), bradycardia, AV blockade.
When used with opioid analgesics, there is a mutual enhancement of the action of the products.
Egilok enhances the effect of hypoglycemic (lowering blood sugar) products. When using Egilok in conjunction with alpha and beta adrenomimetics, the risk of arterial hypotension, bradycardia, and sudden cardiac arrest increases.
Estrogens, NSAIDs (non-steroidal anti-inflammatory products), rifampicin, barbiturates can reduce the hypotensive effect of Egilok.
The drug enhances the action of curare-like muscle relaxants.
Egilok (Egilok) composition:
Active ingredient – metoprolol tartrate 25 mg, 50 mg.
Auxiliary components: cellulose, sodium starch glycolate, silicon dioxide colloidal anhydrous, magnesium stearate, povidone.
In patients with severe heart failure, the dose should be individually adjusted, starting with the lowest concentration.
Against the background of the use of Egilok, an aggravation of peripheral circulatory disorders was observed.
Even in therapeutic doses, Egilok can cause broncho-obstructive complications, especially if the patient has a predisposition in the form of a disease from the broncho-pulmonary system.
In patients with diabetes mellitus and in other patients taking hypoglycemic products, regular monitoring of blood sugar levels is carried out.
When carrying out surgical interventions, etc. , it is necessary to notify the anesthesiologist about taking Egilok.
When prescribing Egilok simultaneously with products that cause depression of the nervous system (hypnotics, tranquilizers, antipsychotics, tranquilizers), the effect may be enhanced, control by a neurologist and psychiatrist is necessary.
In patients whose work and lifestyle requires an increased concentration of attention (including driving a car), it is worth deciding on the appointment of the product, only after a thorough examination of the patient. Start driving a car, etc. after evaluating the individual reaction of the patient’s body to the product for at least a few days.